12 Best Slow Growth Stocks to Invest In

Page 5 of 12

8. Abbott Laboratories (NYSE:ABT)

5-Year Revenue Growth: 5.63%

Dividend Yield: 1.84%

Number of Hedge Fund Holders: 68

Abbott Laboratories (NYSE:ABT) ranks among the best slow growth stocks to invest in. UBS reaffirmed its Buy rating and $158 price target for Abbott Laboratories (NYSE:ABT) on November 21 in response to the company’s agreed acquisition of Exact Sciences.

In the largest acquisition in the medtech sector thus far this year, Abbott Laboratories (NYSE:ABT) signed a formal agreement to buy Exact Sciences at $105 per share. The deal is scheduled for completion in the second quarter of 2026. Abbott’s Diagnostics division is expected to rise by about 300 basis points as a result of the transaction.

Abbott’s medical device businesses, which are primarily focused on diabetes and cardiovascular disease, will now venture into cancer care with this acquisition. Abbott Laboratories (NYSE:ABT) will also add Exact Sciences’ flagship test, Cologuard, which screens for colorectal cancer, to its portfolio.

Beyond Diagnostics, UBS is adamant that Abbott Laboratories (NYSE:ABT) will consistently outperform its competitors in sales and earnings per share starting in 2026, given its medical technology profile and persistent double-digit growth.

Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items.

Page 5 of 12